Company intelligence / Profile preview

Constellation Energy Group

Cambridge, MA, USA

Ownership: Private
Development stage: Other

Overview

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the development of small molecule therapeutics that target epigenetic regulators. The company's research focuses on modulating gene expression to treat cancer and other serious diseases, leveraging its proprietary epigenetics platform. Its lead candidate, pelabresib (CPI-0610), is a selective BET inhibitor currently in Phase 3 clinical trials for the treatment of myelofibrosis. Constellation was acquired by MorphoSys in 2021 for approximately $1.7 billion, and subsequently became part of Novartis following Novartis's acquisition of MorphoSys in 2024.

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

MorphoSysNovartis

Beyond the preview

Go deeper on Constellation Energy Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Constellation Energy Group.

Explore the full profile